Jul 1 |
Aileron Therapeutics to be Included in the Russell Microcap® Index
|
May 30 |
Are Medical Stocks Lagging Sensus Healthcare (SRTS) This Year?
|
May 15 |
Aileron Therapeutics GAAP EPS of -$0.86 beats by $0.16
|
May 15 |
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
|
May 7 |
Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround
|
May 6 |
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
|
May 3 |
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
|
May 2 |
Aileron reports data from Cohort 1 of Phase Ib inhaled IPF treatment trial
|
May 1 |
Aileron announces pricing of underwritten registered direct offering priced at-the-market under Nasdaq rules of up to about $40M
|
May 1 |
Aileron Therapeutics announces positive data from its early stage pulmonary fibrosis treatment trial
|